Nasdaq GlobeNewswire

XBiotech Signs Agreement With Megapharm To Market Xilonix™ In Israel

Del

AUSTIN, Texas, 2016-06-28 14:46 CEST (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, today announced that it has entered into an exclusive licensing agreement with Megapharm Ltd., to commercialize Xilonix™ in Israel for the treatment of advanced colorectal cancer.

Xilonix is currently under accelerated review by the European Medicines Agency (EMA); a decision on approval could come as early as the fourth quarter of 2016. Xilonix also has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of colorectal cancer.

Under terms of the agreement, Megapharm will pay XBiotech an undisclosed upfront fee followed by payments upon the completion of certain commercial and regulatory milestones, including the approval of Xilonix for sale in Israel. In addition, upon this approval, Megapharm will purchase Xilonix from XBiotech at a supply price that is based on a percentage of net sales of the product.

“We are very pleased to partner with Megapharm to bring Xilonix to patients in this important market,” said XBiotech Founder, President and Chief Executive Officer John Simard. “Megapharm has a proven track record of commercial success working with some of the world’s leading biotech and pharmaceutical companies, and their deep experience in oncology makes them an ideal partner. This partnership is consistent with our plan to build marketing and distribution expertise in regional markets that will enable us to focus our internal commercialization efforts in Europe.”

“Xilonix meets a significant unmet need for the growing number of advanced colorectal cancer patients who seek an effective treatment option that is not encumbered by debilitating side effects,” said Megapharm Chief Executive Officer Miron Drucker. An estimated 3,500 people in Israel are diagnosed with colorectal cancer every year.

Founded in 1989 and headquartered in Ra’anana, Israel, Megapharm has partnered with international biotech and pharmaceutical companies to market medicines throughout Israel. “This agreement is an important step in our strategy to expand our oncology portfolio with a truly innovative therapy,” Drucker said. “We are prepared to launch Xilonix as soon as possible.” 

About Colorectal Cancer
Colorectal cancer is the second leading cause of malignancy in the industrialized world.[i] Because the incidence of colorectal cancer increases with economic development and aging, incidence is rising worldwide.[ii] In Europe, approximately 470,000 patients will be diagnosed with colorectal cancer this year, and half will progress and ultimately succumb to the disease.[iii] Disease progression is associated with significant morbidity, functional impairment, and failure of multiple therapies often with substantial toxicities. Patients with advanced disease are thus symptomatic and intolerant to further treatment-related morbidity. New anti-cancer options are needed for patients suffering from advanced colorectal cancer.

About True Human™ Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech’s True Human antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

The first of these therapies, Xilonix, for advanced colorectal cancer, is in Phase III clinical trials in the United States with a Fast Track designation by the U.S. Food and Drug Administration (FDA). In Europe, Xilonix Phase III clinical trials have been completed, and the therapy is under accelerated review following the validation of its Market Authorization Application by the European Medicines Agency (EMA).

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

About Megapharm
Megapharm Ltd. is one of the leading private biotech, pharmaceutical and medical nutrition marketing companies in Israel with a strong biotech orientation, exclusively representing a number of major American and European pharmaceutical companies. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas and diversified segments of the healthcare business. For more information see www.megapharm.co.il.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

______________________
[i]
 Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2095e128.

[ii] United European Gastroenterology (UEG). https://www.ueg.eu/press/releases/ueg-press-release/article/europe-is-falling-behind-america-in-the-fight-against-colorectal-cancer-due-to-low-screening-uptake/. Accessed April, 2016. 

[iii] EuropaColon. http://www.europacolon.com/crcstatistics.php?Action=Crcstatistics. Accessed April, 2016.

         Media liaison U.S.
         Mariann Caprino
         +1 917 242 1087
         
         Media liaison ex-U.S.
         Jonathan Kearney
         +44 20 8618 2755
         Mobile: +44 7725 925 841

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Hitachi Vantara Continues To Bolster Its Global Leadership Team With New Executive Appointments13.12.2017 15:00Pressemelding

SANTA CLARA, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced new appointments to its global leadership team: Mark Ablett has been named senior vice president of global go-to-market (GTM) strategy and Daniel Chong has been named senior vice president of Asia Pacific (APAC). Both will report to the company's chief revenue officer, Hans-Peter Klaey. Ablett previously served as Hitachi Vantara's senior vice president (SVP) of APAC, where he helped Hitachi Vantara's APAC theatre to achieve record growth. In his new role, Ablett will be responsible for developing the company's global GTM strategy, partnering with Hitachi Vantara's customers to help them successfully navigate and execute complex digital transformation journeys. Prior to joining Hitachi, Ablett held executive positions with Juniper Networks and SpectraLink, among others. Chong will assume Ablett's former post as SVP of APAC

DTLR Selects ShopperTrak Traffic Insights to Optimize Store Performance13.12.2017 12:11Pressemelding

Lifestyle retailer uses ShopperTrak to better understand key metrics and customer insights CHICAGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyco Retail Solutions today announced that DTLR Inc., a US lifestyle retailer, has selected its ShopperTrak in-store traffic analytics solution, to provide shopper behavior insights across all 107 stores in 12 states and Washington D.C. Following a successful pilot, DTLR deployed the ShopperTrak perimeter analytics solution and related advisory services to position the importance of shopper traffic, conversion, and other key metrics across the organization. ShopperTrak advisory services utilized include store segmentation, peer grouping, goal setting and field-level training to help better understand shopper traffic and how to best leverage the new data insights. "We sought a vendor who could offer perspective on our operational activities and provide tangible ways to optimize in-store performance," said Frank Long, vice president of

Percona Collaborates with AWS on Database Delivery Service13.12.2017 09:02Pressemelding

Percona Managed Services to Ensure Customers Running Open Source Databases on AWS Take Optimal Advantage of AWS Resources RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced collaboration with Amazon Web Services (AWS) to serve as an AWS Standard Tier Consulting Partner and Amazon Aurora Service Delivery Partner in the AWS Partner Network (APN). Percona provides managed services to support the use of Amazon Elastic Compute Cloud (Amazon EC2), Amazon Relational Database Service (Amazon RDS), and Amazon Aurora on the flexible, scalable, pay-as-you-go AWS. Percona also announced Percona Monitoring and Management 1.5 with improved support for MySQL on Amazon RDS and Amazon Aurora MySQL. Migrating workloads to AWS can be a vital part of improving customer experience, gaining deeper business insights and increasing efficiency. Whether

Upstream Security Revs Up Cloud-Based Cybersecurity for Connected and Autonomous Car Fleets with $9M Series A13.12.2017 09:01Pressemelding

CRV Joins Existing Investors to Accelerate Company's Expansion in the U.S. and Europe as Market for Connected Vehicles and Automotive Cybersecurity Expects to Grow 20x HERZLIYA, Israel, Dec.  13, 2017  (GLOBE NEWSWIRE) -- Upstream Security, pioneer of the cloud-based cybersecurity platform for connected cars and autonomous vehicles, today announced the closing of $9 million in Series A funding, led by CRV (Charles River Ventures). The round included expanded investments from Israeli-based Glilot Capital Partners and Maniv Mobility. Following a $2 million seed funding round in June, the company will use the latest investment to expand its R&D program and continue building out its world-class engineering and security research teams, and open marketing and sales offices in the United States and Europe. The company is well-resourced to secure the 60 million connected cars on the road today that include commercial trucks, vans, buses and private vehicles, as well as take advantage of

Percona Monitoring and Management 1.5 Provides Enhanced Cloud Support, Improved Interface13.12.2017 09:00Pressemelding

Highlights Include Improved Support for MySQL on Amazon RDS and Amazon Aurora, More Efficient Data Collection, Faster Time to Support Resolution RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced Percona Monitoring and Management 1.5, the latest release of the company's free and open source platform for managing and monitoring MySQL® and MongoDB® performance. This new release improves support for MySQL on Amazon Relational Database Service (Amazon RDS) and Amazon Aurora, which simplifies configuration and usage, provides more efficient data collection and delivers faster resolution of Percona Support tickets. Organizations are increasingly choosing to run MySQL on Amazon RDS or use Amazon Aurora and require the same insight into database performance that they have with their on-premises deployments to be successful. Percona Monitoring and Man

Ammo Incorporated Releases STREAK Visual Ammunition12.12.2017 15:00Pressemelding

SCOTTSDALE, Ariz., Dec. 12, 2017 (GLOBE NEWSWIRE) -- AMMO, Inc. (OTC:POWW), a technology leader and premier American ammunitions manufacturer, today announced its newest product offering, STREAK Visual Ammunition.  AMMO, Inc. holds the exclusive worldwide rights for the incredible patented technology used to make the STREAK products. STREAK is one of the most technologically advanced ammunition to hit the market in decades. "We are beyond excited to bring STREAK Visual Ammunition to the market.  Our acquisition of the exclusive rights for the STREAK technology is a game changer for both our company as well as the shooting industry.  Once you shoot with STREAK and you can actually see your projectile travel throughout its path, you will be bored by shooting normal ammunition," said AMMO, Inc.'s CEO, Fred Wagenhals. Unlike conventional tracers, STREAK rounds are NOT an incendiary, they don't use burning metals to generate light. Replacing fire-hazard burning metals is a non

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom